| Keven J Nevil, MD | |
|
930 Sw Abbey St Ste B, Newport, OR 97365-4820 | |
| (541) 574-7235 | |
| Not Available |
| Full Name | Keven J Nevil |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 930 Sw Abbey St Ste B, Newport, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497779136 | NPI | - | NPPES |
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174888010 PECOS PAC ID: 2466353529 Enrollment ID: O20040204000304 |
News Archive
The current standard practice of giving infants and children 100 percent oxygen to prevent brain damage caused by oxygen deprivation may actually inflict additional harm, researchers at UT Southwestern Medical Center have found.
The Moscow Times examines a potential shift in Russia's public health priorities as programs funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria begin to phase out.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A new theory about early human adaptation suggests that our ancestors capitalized on their capacities for play to enable the development of a highly cooperative way of life.
› Verified 1 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1801847066 PECOS PAC ID: 2466353529 Enrollment ID: O20061104000163 |
News Archive
The current standard practice of giving infants and children 100 percent oxygen to prevent brain damage caused by oxygen deprivation may actually inflict additional harm, researchers at UT Southwestern Medical Center have found.
The Moscow Times examines a potential shift in Russia's public health priorities as programs funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria begin to phase out.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A new theory about early human adaptation suggests that our ancestors capitalized on their capacities for play to enable the development of a highly cooperative way of life.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Keven J Nevil, MD Po Box 1189, Corvallis, OR 97339-1189 Ph: () - | Keven J Nevil, MD 930 Sw Abbey St Ste B, Newport, OR 97365-4820 Ph: (541) 574-7235 |
News Archive
The current standard practice of giving infants and children 100 percent oxygen to prevent brain damage caused by oxygen deprivation may actually inflict additional harm, researchers at UT Southwestern Medical Center have found.
The Moscow Times examines a potential shift in Russia's public health priorities as programs funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria begin to phase out.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
A new theory about early human adaptation suggests that our ancestors capitalized on their capacities for play to enable the development of a highly cooperative way of life.
› Verified 1 days ago
Dr. Michael Paul Adler, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 930 Sw Abbey St Ste B, Newport, OR 97365 Phone: 541-574-7235 | |
Dr. James Gerard Zolzer, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 930 Sw Abbey St Ste B, Newport, OR 97365 Phone: 541-574-7235 | |
Mr. Daniel Duane Kort, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 130 Nw 19th St., Suite A, Newport, OR 97364 Phone: 541-264-8332 Fax: 541-264-8376 | |
Dr. Diane Louise Leyba, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 930 Sw Abbey St Ste B, Newport, OR 97365 Phone: 541-574-7235 | |
Karen Fleenor Bunn, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 930 Sw Abbey St Ste B, Newport, OR 97365 Phone: 541-574-7235 | |
Dr. Ian Ross Donald, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 775 Sw 9th St Ste H, Newport, OR 97365 Phone: 541-574-4767 Fax: 541-574-4747 | |
Michael Swift, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 930 Sw Abbey St Ste B, Newport, OR 97365 Phone: 541-574-7235 Fax: 541-812-2077 |